Skip to main content
. Author manuscript; available in PMC: 2017 Jul 15.
Published in final edited form as: Clin Cancer Res. 2016 Mar 30;22(14):3488–3498. doi: 10.1158/1078-0432.CCR-15-2290

Figure 2. Assessment of GIV/LVI risk model.

Figure 2

(A) ROC curves comparing the prognostic accuracy of the GIV/LVI risk classifier (high vs low risk) with clinical model alone, or GIV and clinical model combined. Area under the curve (AUC) for recurrence at 3 years (shown in brackets) shows the utility of including GIV analysis in recurrence risk assessment. (B) Kaplan-Meier recurrence-free survival (RFS) based on MMR status and the GIV/LVI risk classifier for T3, surgery-alone patients in the training set. (C, D) Kaplan-Meier RFS based on the GIV/LVI risk classifier for T3, pMMR, surgery-alone patients in the internal testing (C) and independent validation sets (D). ROC = receiver operator characteristics. LVI = lymphovascular invasion. dMMR/pMMR = deficient/proficient mismatch repair.